Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.

Progress in neuro-psychopharmacology & biological psychiatry - 20 Mar 2025

Zhang Hanyu, Zhou Zengyuan, Gu Jie, Lin Yingnan, Yan Yunyun, Chen Xiaonan, Fan Meixiang, Huang Yanyan

Abstract excerpt

BACKGROUND: Lewy body dementia (LBD) is the second common dementia, with unclear mechanisms and limited treatment options. Dyslipidemia has been implicated in LBD, but the role of lipid-lowering drugs remains underexplored. This study aims to investigate the association between lipid traits, drug targets, and LBD risk using Mendelian Randomization (MR) analysis. METHODS: We performed univariable and multivariable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol
Share to Cholesterol Ester Transfer Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Hydroxymethylglutaryl CoA Reductases

Share to Hypolipidemic Agents

Share to Lewy Body Disease

Share to Lipid Metabolism

Share to Mendelian Randomization Analysis

Source

Identifiers

PMID: 39929371
DOI: 10.1016/j.pnpbp.2025.111282

Genes

ANGPTL3
CETP
HMGCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization.PMID 39929371Read ↗

Elevated serum LDL-C increases the risk of Lewy body dementia: a two-sample mendelian randomization study.Semantic proximity Read ↗

Exploring the causal effects of serum lipids and lipidomes on lewy body dementia: a Mendelian randomization study.Semantic proximity Read ↗

Lipid lowering and Alzheimer disease risk: A mendelian randomization study.Semantic proximity Read ↗

Association between genetically proxied lipid-lowering drug targets, lipid traits, and amyotrophic lateral sclerosis: a mendelian randomization study.Semantic proximity Read ↗

Undetected Association Between Fatty Acids and Dementia with Lewy Bodies: A Bidirectional Two-Sample Mendelian Randomization Study.Semantic proximity Read ↗

Genetic Associations of Lipid-Lowering Drugs and Parkinson’s Disease: A Mendelian Randomization StudySemantic proximity Read ↗

Causal relationship between cholesterol-lowering therapy and Alzheimer Disease: evidence from genetic correlation and Mendelian randomization studySemantic proximity Read ↗

Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.Semantic proximity Read ↗

Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian Randomization.Semantic proximity Read ↗

LDL-c Lowering, Ischemic Stroke, and Small Vessel Disease Brain Imaging Biomarkers: A Mendelian Randomization StudySemantic proximity Read ↗

Causal Association between Circulating Metabolites and Dementia: A Mendelian Randomization StudySemantic proximity Read ↗

Low-Density Lipoprotein Cholesterol and Dementia Risk: Integrating Mendelian Randomization and Target Trial Emulation Within the Heart–Brain AxisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.